ERBB2 and cancer: This also applies to many other cancer types such as colon cancer, ovarian cancer and bladder cancer, and small molecular weight chemotherapeutic agents or antibodies that target EGFR and HER2 and inhibit their activity have been proven to be clinically effective in overexpressing cancers (Hynes and Lane, 2005; Shepherd et al, 2005; Thatcher et al, 2005; Moore et al, 2007; Mok et al, 2009).